TORONTO, Aug. 31, 2020 (GLOBE NEWSWIRE) — Datametrex AI Limited (“Datametrex” or the “Company“) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce the appointment of Don Shim, CPA, CA as the new Chief Financial Officer (“CFO”).
This new addition to the Company’s executive leadership team brings nearly 20 years of financial experience in accounting and financial control along with a combination of private and public companies in a variety of industries. These include cannabis, resource, and financial services. Don will work to ensure Datametrex’s financial health through strategic planning and management of the company’s finances.
- Mr. Shim has led a successful accounting and finance career in both the US and Canada. He brings a wealth of knowledge to the team with his expertise in auditing publicly- traded junior mining companies and high-tech industries. Member of the Chartered Professional Accountants of British Columbia and a Certified Public Accountant registered in the State of Illinois, United States.
- Audit partner on numerous audit engagements for various publicly traded companies, primarily focusing on junior mining, oil and gas, pharmaceutical, and high-tech industries.
- Mr. Shim also assisted various start-up companies in achieving public listings on the TSX Venture Exchange, Canadian Securities Exchange and the OTC Market.
- In addition, Mr. Shim teaches accounting at a local college in Vancouver and acts as a facilitator at CPA Western School of Business, mentoring CPA candidates enrolled in the CPA Professional Education Program.
“I am thrilled to join Datametrex and this impressive leadership team with a history of growing great companies, and I am happy to be a part of this enterprise,” said Don.
“On behalf of the executive team and our Board of Directors, I would like to thank Steve Kang for his dedication and hard work during his tenure as CFO. I wish Steve nothing but success in his future endeavours,” said Paul Haber, audit committee chair of the Company.
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
PURA Plows Forward With Farmersville Brands And Stock Dividend
Dallas, Texas–(Newsfile Corp. – September 30, 2020) – Puration, Inc. (OTC Pink: PURA) management today communicated assurance that the company’s Farmersville Brands strategy to include the acquisition of 72-acre property in Farmersville, Texas and infused with a $100 million planned investment is moving forward. Management also confirms intentions to promptly execute on the distribution of a previously announced stock dividend. With both coming at the end of the third quarter, management decided to close the quarter before the definitive execution of the property acquisition and the dividend. PURA expects to make prompt definitive moves on both next week. Management is also pleased to highlight the impending initiation of a third production run this year of its EVERx CBD Sports Water in conjunction with ongoing consistent sales in the face of this year’s pandemic challenges.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64943
The Top Reasons Lithium Prices Will Soon Spike Higher Again
Houston, Texas–(Newsfile Corp. – September 30, 2020) – The world could run into a massive lithium supply crunch.
Thanks in part to the electric vehicle boom that doesn’t look to cool off any time soon.
In fact, “A global push for EV adoption, helped by government subsidies and incentives, means that demand for lithium is not going away. Companies like Volkswagen, Ford, Mercedes and Amazon having started shifting their focus to electric vehicles,” reports Bloomberg.
According to the Boston Consulting Group, by 2025, EVs could account for a third of all auto sales. By 2030, EVs could surpass combustion engine vehicles with a market share of 51%.
Helping to fuel the boom, Tesla just signed a lithium ore supply deal with Piedmont Lithium.
“The initial five-year agreement implies that Piedmont will supply about a third of its planned 160,000-tonnes-per-year spodumene concentrate produce from its deposits in North Carolina. Both companies have an option to extend the deal for another five years,” added Reuters.
With demand increasing, it’s only a matter of time before lithium prices spike again.
E3 Metals Corp. (TSXV: ETMC) (OTC Pink: EEMMF) Could Be a Big Part of the Lithium Boom
E3 Metals Corp. just hosted the Energy Minister, Sonya Savage, from the Government of Alberta at the Company’s offices in Calgary.
During this visit, the government announced it has assembled a five-member panel of experts from the metals and mining industry whose strategic advice will help government unlock the province’s vast mineral potential, including lithium. The panel will support the province in its efforts to diversify its economy and become a world leader in mineral resource production.
“We are very happy to host the Minister of Energy at our offices today. This announcement solidifies the province’s commitment for the development of critical minerals. E3 Metals is on the forefront of lithium development in Alberta, a critical mineral that can be produced on the backbone of the oil industry. Alberta has a skilled energy labour force already in place that is well positioned to support an emerging minerals sector,” said Chris Doornbos, President and Chief Executive Officer of E3 Metals.
“As E3 Metals works to commercialize lithium production in Alberta, we are excited to participate in this broader effort to position Alberta as an international player in a world increasingly focused on battery materials,” he added.
In addition, according to Sonya Savage, Minister of Energy, Government of Alberta, “We (the Alberta government) need to take bold action to diversify our economy by exploring… minerals. Our government’s efforts will support the development… of the mineral sector including the ground breaking work that is being done by Alberta companies such as E3 (Metals). Our ultimate goal (is to become) a global destination for mineral investment exploration and development.”
The announcement by the province complements the Canada-U.S. Joint Action Plan on Critical Minerals Collaboration, which focuses on securing and developing critical mineral supply chains. Lithium, graphite, cobalt and rare earth elements, all of which play an important role in the production of lithium-ion batteries and the energy storage sector, are listed as critical minerals. To date, many other developed economies have put in place a critical minerals strategy including the European Union, Japan, Korea and Australia.
For more information, visit the company’s website at https://www.e3metalscorp.com
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media and E3 Metals Corp. Winning Media has been paid two thousand dollars for advertising and marketing services for E3 Metals Corp. We own ZERO shares of E3 Metals Corp. Please click here for full disclaimer.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64942
PAOG Cannabis Pharmaceutical Research Initiative Gains New Traction
Sandusky, Ohio–(Newsfile Corp. – September 30, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today indicated plans to reveal new information on the Company’s initiative to expand its cannabis pharmaceutical treatment research beyond its current focus on Chronic Obstructive Pulmonary Disease (COPD).
In a media interview scheduled for release on Friday, October 2nd, PAOG Jim DiPrima will highlight a new pharmaceutical cannabis research expert resource engaged by the company to bring new industry recognized expertise to move PAOG’s cannabis pharmaceutical asset forward.
On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
In an initial scientific evaluation as a treatment for COPD, RespRx has demonstrated effecting significant increases in respiration rate, tidal volume and inspiratory air flow rate. Overall data from the evaluation demonstrated that RespRx can significantly improve inspiratory lung functions in instances of moderate pulmonary fibrosis.
With RespRx now in house, PAOG has engaged multiple new experts from both the university and commercial medical research community to evaluate the RespRx formula, the formulation process and the test results.
The expert evaluation has reviewed RespRx in conjunction with other publicly available cannabis treatment research. Two studies in particular, both of which highlight the research behind GW Pharmaceuticals’ cannabinoid treatments, shed light on PAOG’s wider opportunity stemming from RespRx, the process to derive RespRx and the clinical trials to date behind RespRx.
One of the two studies is focused on CBD and the other on THC. The research seems to indicate CBD has both an impact on hyper-immune responses that might result in conditions like a cytokine storm which impacts many COVID-19 patients, and positive stimulation of immune responses that fight bad cells. The THC report seems to validate its ability to relieve pain, but it also indicates immune response manipulation capabilities to include anti-inflammatory reactions and the stimulation of immune responses to fight bad cells.
CBD Research – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173676/
THC Research – https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219460/
In summary, existing publicly available cannabis treatment research further supports the research findings behind RespRx, and at the same time, the publicly available research sheds light on the expanded potential of PAOG’s RespRx overall technology.
The growing body of cannabis research is building convincing evidence behind how specific cannabinoids can beneficially impact specific immune responses. The research behind RespRx demonstrates how the process to derive RespRx can be manipulated to target specific cannabinoid extractions. Accordingly, as advancing cannabis research unveils further evidence behind how specific cannabinoids beneficially impact specific immune responses, PAOG is optimistic that it can utilize its overall cannabis extraction process to effectively derive formals with high concentrations of target cannabinoids. Hence, PAOG sees a more broad future of developing cannabis treatments beyond COPD.
In conjunction with PAOG’s acquisition of RespRx, the company also recently acquired a hemp cultivation business from Puration, Inc. (OTC Pink: PURA) to develop a proprietary cultivar to support PAOG’s cannabis pharmaceutical treatment objectives.
PAOG has announced plans with PURA to expand upon PAOG’s hemp cultivation business to develop a proprietary hemp cultivar. PAOG and PURA are partnering on PURA’s Farmersville Brands initiative.
PAOG’s Farmersville cultivar development operation will include a lab and an environmentally controlled indoor growing facility. PAOG is working with current cultivars to evolve and produce an ideal plant with full spectrum, high CBD yields to support ongoing RespRx development and to support future CBD pharmaceutical developments.
PAOG is exploring opportunities to engage with university research in partnership with its hemp cultivar development initiative.
PURA recently announced a year long initiative to transition PURA from a CBD sports beverage manufacturer into a hemp conglomerate built on lifestyle brand with a broad CBD consumer products reach, and a leading industrial hemp initiative. The brand name is Farmersville Brands and as part of their strategy, PURA has entered into a letter of intent (LOI) agreement to acquire 72 acers of agricultural property in Farmersville, Texas. PURA’s year long initiative includes plans to see the Farmersville Brand strategy infused with a $100 million investment.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64940
Cannabis4 weeks ago
3 Rivers Biotech to Establish Genetic Fingerprinting and Pathogen Testing Lab
Cannabis3 weeks ago
Rapid Screening Tests Are Still Struggling to Keep up with Demand
Cannabis4 weeks ago
DGDM’s Disruptive Pesticide Product Targeted to MJ Growers Passes Testing Trials During Pre-EPA Certification Period
Cannabis3 weeks ago
DGDM Provides Further Analysis of Specific Trial Testing Results of Its Disruptive Pesticide Product Targeted at MJ Growers
Cannabis2 weeks ago
Sixth Wave Innovations Announces Collaborative “Green” Test Initiatives with Mining and Process Solutions (Australia)
Cannabis4 weeks ago
Fernhill Beverage Branches Out for Success!
Cannabis4 weeks ago
MediPharm Labs Enters Growing Latin American Medical Cannabis Market; Enters Supply Agreement With Cann Farm Peru
Cannabis3 weeks ago
Monument Health Chooses Nuance Dragon Ambient eXperience to Transform Physician-Patient Encounters with Ambient Clinical Intelligence